Rituximab is an exciting monoclonal antibody drug approved for treating B-cell lymphomas and its target is the CD20 antigen which is expressed on the surface of B cells. In recent years, the variable efficacies of rituximab among different lymphoma patients have become an important clinical issue and urgently need to be solved for further development of antibodies with enhanced efficacies. In this work, atomic force microscopy (AFM) was used to investigate the nanoscale distribution of CD20 on the surface of tumour B cells from lymphoma patients to examine its potential role in the clinical therapeutic effects of rituximab. By performing ROR1 fluorescence labelling (ROR1 is a specific tumour cell surface marker) on the bone marrow cells prepared from B-cell lymphoma patients, the tumour B cells were recognized, and then AFM tips carrying rituximabs via polyethylene glycol crosslinkers were moved to the tumour cells to probe the specific CD20-rituximab interactions. By applying AFM single-molecule force spectroscopy (SMFS) at the local areas (500×500 nm 2 ) on the surface of tumour B cells, the nanoscale distributions of CD20 on the surface of tumour B cells were mapped, visually showing that CD20 distributed heterogeneously on the cell surface. Bone marrow cell samples from three clinical B-cell lymphoma cases were collected to analyze the binding affinity and nanoscale distribution of CD20 on tumour cells. The experimental results showed that CD20 distribution on tumour cells were to some extent related to the clinical therapeutic outcomes while the CD20-rituximab binding forces did not have distinct effects to the clinical outcomes. These results can provide novel insights in understanding the rituximab's clinical efficacies from the nanoscale distribution
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Introduction
Non-Hodgkin lymphomas (NHLs) are the solid tumours of the immune system (Shankland et al., 2012) and encompass many subtypes according to the combination of morphology, immunophenotype, genetic, molecular and clinical features of the tumours (Campo et al., 2011) . Approximately 85% of NHL in adults arise from B cells (Cheson & Leonard, 2008) , and the rest are T-cell origin (Kuppers, 2005) . Follicular lymphoma and diffuse large B-cell lymphoma are the two most common B-cell NHLs, comprising 60% of new B-cell NHL diagnoses each year in North America (Morin et al., 2011) . The approval of rituximab in 1997 revolutionized the clinical treatment of B-cell NHL. Rituximab is a chimeric human-mouse monoclonal antibody that specifically binds to the CD20 antigen on the surface of normal and tumour B-cells. CD20 is absent from haematopoietic stem cells, thus normal B-cells are able to regenerate after the rituximab treatment and return to pretreatment levels within several months or even years (Leandro, 2013) . In vitro studies indicate that the binding of rituximab to CD20 causes the death of target cells through three mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and direct induction of programmed cell death (Cartron et al., 2004) . Though the exact contribution of these mechanisms to rituximab's killing effect in vivo remain largely unknown (Tsirigotis & Economopoulos, 2008) , rituximab proved to be very effective in clinical practice either by itself or when combined with chemotherapy, significantly improving the response rates and survival outcomes of B-cell NHL patients (Molina, 2008 (Maloney, 2012) and whether such new antibodies will be clinically superior to rituximab therapy remains to be seen (Weiner, 2010) . In recent years, requirements that developing new antibodies to provide effective therapies for those patients who are insensitive or develop resistance to rituximab are increasingly urgent (Alduaij & Illidge, 2011) . Addressing the problem of rituximab's variable efficacies among different patients will greatly promote the development of new antibody drugs and thus will improve the life quality of patients.
Cancer is a type of highly heterogeneous diseases. Tumour formation involves the co-evolution of neoplastic cells together with extracellular matrix, tumour vasculature and immune cells, and all of these elements contribute to the tumour heterogeneity in and among tumours (Junttila & Sauvage, 2013) . Tumour genotypes are variable between patients, and in the same patient remarkable intratumour heterogeneity might also exist between different geographical regions in the same tumour (Bedard et al., 2013) , and perhaps every cancer cell is unique (Marte, 2013) . In fact, heterogeneity between single cells can be observed in populations of monoclonal cells that have been cultured under identical conditions (Pelkmans, 2012) . Therefore, investigating the cellular physiological activities at single-cell and single-molecule levels is the inevitable trend in life sciences and this will play an important role in the era of personalized medicine. Many single-cell and singlemolecule techniques have emerged in the past decades, and among these atomic force microscopy (AFM) (Binnig et al., 1986) is an amazing instrument with unique advantages. AFM has nanometre spatial resolution and can work in liquids, which allows us to investigate the cellular physiological activities at the nanoscale level in native conditions. AFM can detect the nanoscale distribution of membrane proteins on the surface of single cells by using functionalized tips (ligands or antibodies were linked to the tips via spacer molecules) to obtain force curves on the cell surface, and this technique is called single-molecule force spectroscopy (SMFS) (Muller et al., 2009) . SMFS has been widely used to investigate the distribution of specific proteins on the cell surface, but to date all of these researches were performed on isolated proteins or on cells grown in vitro (Dufrene et al., 2011) . We know that the remarkable difference between in vivo environment and in vitro environment often causes that the experimental results obtained in vitro can not faithfully reflect the properties of the same molecules in vivo (Oddershede, 2012) . Viewed from this point, performing biochemical researches directly on the malignant cells from the clinical cancer patients will have great clinical significance.
Recent researches about receptor tyrosine kinase-like orphan receptor 1 (ROR1) have highlighted the potential significance of ROR1 in the treatment of B-cell chronic lymphocytic leukaemia (CLL) and B-cell NHL (Rebagay et al., 2012) . ROR1 is exclusively expressed on tumour cells but not on virtually all normal cells (Zhang et al., 2012) and hence it is a tumour specific biomarker. Evidence indicated that ROR1 is expressed on many B-cell NHL tumour cells, e.g. mantle cell lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma and follicular lymphoma (Barna et al., 2011) . Researchers have investigated the CD20 expression levels of lymphoma patients by flow cytometry (Huh et al., 2001; Perz et al., 2002) , but due to the lack of adequate tumour-specific molecules, these researches contained the results both on tumour B cells and normal B cells. Besides, due to the 200 nm resolution limit, optical microscopy can not reveal the detailed distribution of CD20 on the cell surface. Now with ROR1, we can recognize the tumour B cells from normal B cells and then investigate the biophysical and biochemical properties of CD20 antigen directly on tumour cells from lymphoma patients, which will bring novel information with direct clinical significance. Here we applied AFM-based SMFS to quantitatively characterize the nanoscale distribution of CD20 on the tumour cells from three B-cell NHL patients under the assistance of ROR1 fluorescence labelling and analyze the relationship between CD20 distribution and clinical rituximab efficacies.
Materials and methods

Sample preparation
The process of sample preparation was according to the reference (Li et al., 2013a (Li et al., , 2013b . Bone marrow cell samples from three B-cell NHL patients (the three patients were splenic marginal zone B-cell lymphoma, small B-cell lymphoma and diffuse large B-cell lymphoma, respectively) who had bone marrow infiltration were obtained by the clinicians in Chinese Affiliated Hospital of Military Medical Academy of Sciences using bone marrow aspiration method. The bone marrow samples were dropped to the glass slides which were treated by poly-L-lysine solution (poly-L-lysine was used to attach cells onto the glass slides by electrostatic adsorption). Then the cells were chemically fixed for 30 min by 4% paraformaldehyde. Next, cells on the glass slides were labelled by using goat-anti-human ROR1 antibody (R&D systems, Minneapolis, MN, U.S.A.) and subsequent FITC-conjugated donkey-antigoat IgG secondary antibody (KangChen company, Shanghai, China). Because only tumour B cells express ROR1 and normal cells do not express ROR1, we can recognize the tumour B cells from the fluorescence images of the ROR1-labelled cell samples. For negative control experiments, peripheral blood cells from lymphoma patients were used for ROR1 fluorescence labelling. The fluorescence images were obtained on a Nikon inverted fluorescence microscope (Tokyo, Japan) and blue light was used for excitation. For AFM imaging and SMFS force measurements, the glass slide cell samples were placed in a Petri dish in phosphate buffered saline (PBS) and then the Petri dish was put on the AFM stage.
Tip functionalization
For tip functionalization, the NHS-PEG3500-MAL (JenKem Technology, Beijing, China) crosslinker molecule was used. The probe used in the study was silicon nitride with a nominal spring constant of 0.01 N/m (Bruker, Santa Barbara, CA, U.S.A.). Commercial rituximab (10 mg/mL) was obtained from Chinese Affiliated Hospital of Military Medical Academy of Sciences. The process of tip functionalization was according to the protocol in the reference (Stroh et al., 2004; Li et al., 2013a) . Briefly, the AFM tips were first coated by a layer of NH 2 by vapour deposition using aminopropyltriethoxysilan and N,N-diisopropylethylamin (Sigma-Aldrich, Saint Louis, MO, U.S.A.). The NHS end of the polyethylene glycol (PEG) linker can covalently bind to the NH 2 on the tips. Then rituximabs were treated by N-succinimidyl-3-(acetylthio) propionate (SATP) (Thermo Scientific, Rockford, IL, U.S.A.) to form SH group. The MAL end of the PEG linker can bind to the SH group of rituximab to form covalent disulfide bond.
Atomic force microscopy
AFM imaging and force measurements were performed using a Bioscope Catalyst AFM (Bruker, Santa Barbara, CA, U.S.A.) which was set on a Nikon inverted fluorescence microscope (Fig. 1) . The experiments were carried out in PBS at room temperature. The exact spring constant of the functionalized probe was calibrated by thermal noise method (Hutter & Bechhoefer, 1993) . Before measurements, the deflection sensitivity of the functionalized probe was calibrated by obtaining force curves on the bare area of the glass slide. Under the guidance of ROR1 fluorescence recognition, functionalized tips were moved to the shining cells (tumour cell). The morphologies of the tumour cells were obtained by AFM imaging. Large size scanning was first performed to image the whole tumour cell, and then small size scanning was performed to image the nanostructures of tumour cells. All AFM images were recorded with a resolution of 256×256 pixels at contact mode and the scan rate was 1 Hz. The scan force was 400 pN. In order to characterize the nanoscale distribution of CD20 on the surface of tumour cells, the method of adhesion force map was used, as described in the reference (Li et al., 2013b) . Briefly, arrays of force curves (16×16) were obtained in the local areas (500×500 nm 2 ) on the surface of tumour cells with functionalized tips. After computing the molecular binding forces from these force curves, the adhesion force maps were constructed by applying image process program. For comparison, arrays of force curves were also obtained on healthy cells (red blood cells) that did not display fluorescence. For specific molecular force verification, force curves were obtained on tumour cells after adding free rituximabs to block the CD20s on the cell surface. Due to that the molecular force measured by SMFS is related to the loading rate of the tip (Muller et al., 2009) , all force curves in the study were obtained at the same loading rate. Figure 1 shows the integrated AFM-fluorescence microscopy experimental platform and bone marrow cells prepared from clinical lymphoma patients. Bone marrow infiltration universally existed in B-cell NHLs (Sehn et al., 2011) . In the bone marrow cells from NHL patients with bone marrow infiltration, tumour cells accounted for the minority and healthy cells accounted for the majority. Both tumour B cells and normal B cells express CD20 antigen. Previous researches about the CD20-rituximab interactions were commonly performed on tumour cell lines (Li et al., 2009) or normal cells (Huh et al., 2001; Perz et al., 2002) . Cells grown in 2D systems do not accurately recapitulate the structure, function, or physiology of cells in vivo (Derda et al., 2009) , meaning that the experiment conclusions can not completely reflect the cellular and molecular behaviours in vivo. Besides, tumour cells are very different from normal cells (Hanahan & Weinberg, 2011) , meaning that the drug-target molecular interactions on tumour cells may be different from that on normal cells. Therefore, investigating the CD20-rituximab interactions directly on tumour B cells from clinical patients can provide novel information which is useful for understanding the rituximab action and designing better drugs. In the era of personalized medicine, investigating the physiological and pathological features of tumour cells for each patients is very important for exactly predicting the efficacy of the therapy (Hamburg & Collins, 2010) . AFM can probe the nanoscale cellular physiological activities, but it is a nonspecific tool. In order to investigate the behaviours of tumour cells from healthy cells, we need to firstly recognize them. The integrated use of AFM and fluorescence microscopy allows us to probe the nanoscale behaviours of tumour cells from healthy cells under the guidance of tumour-specific fluorescence labelling. In recent years, researchers have combined AFM and fluorescence microscopy to investigate many cellular physiological activities, e.g. candida-macrophage intractions (El-Kirat-Chatel & Dufrene, 2012), matrix remodelling (Kirmse et al., 2011) , exocytosis of lamellar bodies (Hecht et al., 2012) , providing novel insights into the cell biology. Here we combined AFM-fluorescence microscopy to investigate the nanoscale distribution of CD20 on the tumour B cells from lymphoma patients.
Results and discussion
We first performed ROR1 fluorescence experiments on peripheral blood cells from clinical B-cell NHL patients and the results were shown in comprising as few as one cell per 10 9 haematologic cells in the blood of patients with metastatic cancer (Nagrath et al., 2007) . Besides, the lymphoma patients were not metastatic cases and it is likely that the peripheral blood from the lymphoma patients do not have cancer cells. In fact, from the fluorescence images (Fig. 2B,D) , we can see that the peripheral blood cells did not exhibit fluorescence. This is because the normal cells do not express ROR1 and thus the cells did not exhibit fluorescence after the ROR1 labelling procedure.
Then we performed ROR1 fluorescence experiments on bone marrow cells from clinical B-cell NHL patients and the results were shown in Figure 3 . From the optical bright field images (Fig. 3A,D) , we can see many cells in the vision range. From the fluorescence images (Fig. 3B, E) , we can see a few cells which exhibited green light. From Figure 2 , we can see that there were no ROR1 on the peripheral blood cells from lymphoma patients. But when performing ROR1 experiments on the bone marrow cells, there were some cells which exhibited fluorescence. This is because that for lymphoma patients who had bone marrow infiltration, there were tumour cells in the bone marrow. The green fluorescence of the cells in Figures 3(B,E) indicated that they were tumour cells. Figures 3(C,F) were the overlay images of optical bright field images and fluorescence images. The insets in Figures 3(C,F) were the enlarged views of the tumour cells denoted by the dashed squares. When B-cell NHL patients were treated with rituximab, both normal B cells and tumour B cells were killed by rituximab. Hence, strictly speaking, rituximab is not a tumour specific drug. The loss of normal B cells can cause several adverse effects, such as urticaria, fever, chills, hypotension, rigors, bronchospasm and angioedema (Maloney, 2012) . ROR1 has been demonstrated to be a specific tumour cell surface molecule (Barna et al., 2011; Zhang et al., 2012) . It is highly expressed on the surface of B-cell CLL cells and some B-cell NHL cells, whereas normal cells (including normal B cells) do not express ROR1 (Uhrmacher et al., 2011) . Recent researches indicated that ROR1 is not only expressed on the haematopoietic tumour cells but also expressed on a large variety of cancer cells(such as ovarian, colon, lung, skin, pancreatic, testicular, bladder, uterus, prostate and adrenal), particularly those cancers that have high-grade histology (Zhang et al., 2012) . Consequently, due to the excellent specificity, targeting ROR1 will maximize effectiveness and minimize off-target toxicities (Rebagay et al., 2012) , which may thus bring novel progress in the treatment of ROR1-expressing cancers (Baskar et al., 2012) .
After recognizing the tumour cells from normal cells by ROR1 fluorescence labelling, we first got the detailed morphological information of tumour cells by AFM imaging, as shown in Figure 4 . Figure 4A was the overlay image of optical image and fluorescence image. The fluorescence indicated that the cell in Figure 4A was a tumour cell. Under the guidance of fluorescence, AFM tip was moved to the tumour cell to obtain the morphology images. Figures 4(B,C) were the AFM height image and deflection image of the tumour cell, respectively. The scan size was 15.8 μm. The colour scale of the height image and deflection image was 15 μm and 600 nm, respectively. The nanostructures of the tumour cell were acquired by zooming into the local area of the cell surface (denoted by the white square in Figure 4C ). Figures 4(D,E) were the AFM height image and deflection image of the local area on the surface of tumour cell. We can see the tumour cell exhibited a rough and undulant morphology at the nanoscale. For contrast, we also got the morphology of normal cells (red blood cells). Red blood cells can be easily discerned by their special oval biconcave disk shape from the optical image. Figure 4(F) was the optical bright field image of a red blood cell. In the fluorescence image, red blood cells did not exhibit fluorescence. This is because that red blood cells are healthy cells and they do not express ROR1. Figures 4(G,H) were the AFM height image and deflection image of the red blood cell. The scan size was 15 μm. The colour scale of the height image and deflection image was 8 μm and 600 nm, respectively. The AFM images clearly revealed the special morphology of red blood cells.
We know that optical microscopy has 200 nm resolution limit and this means that it can not reveal the fine structures of the cells. Despite electron microscopy can resolve the cellular nanostructures, it requires that cells be fixed and dried, meaning that it cannot investigate the behaviours of live cells. With AFM, we can obtain the real-time changes of nanostructures (such as lamellipodium, filopodia, cytoskeleton) of live cells during cellular physiological activities in liquids (Li et al., 2013c) , allowing us to better understand the cell biology. Due to requirements of the fluorescence labelling procedures, chemical fixatives were used here and the morphologies of chemically fixed tumour cells were obtained. In the future, we want to investigate the behaviours of living tumour cells from clinical patients. In this situation, we should isolate and collect tumour cells, e.g. by flow cytometry (Suzuki et al., 2008) . Besides, due to the suspended trait of the lymphoma cell, we should develop adequate methods to immobilize them for living cell AFM imaging, e.g. micro-well array chip (Li et al., 2013c) and thin film having small pores (Ando, 2012) . Investigating the behaviours of living tumour cells from patients will enable us to detect and monitor the physiological properties of living tumour cells (e.g. the cellular changes after the stimulation of drugs), bringing novel information that is closer to the real cellular activities. Figure 5 shows the molecular force measurement results on tumour cells and normal cells (red blood cells) with functionalized tips by applying SMFS technique. Figure 5 (A) was a typical force curve with specific CD20-rituximab molecular binding when using functionalized tips to obtain force curves on the surface of tumour cells. At the force curve mode, the AFM tip first approached the cell and then retracted from the cell in the vertical direction. Therefore, each force curve includes two portions, approach curve and retract curve. In the approach stage, before the tip contacted the cell, the deflection of the AFM cantilever kept constant and the force curve was flat (the I portion in Fig. 5A ). After the tip contacted the cell, the deflection of the AFM cantilever changed and the force curve became bent (the II portion in Fig. 5A ). In the retracting stage, the AFM tip withdrew from the cell and to its original position. If the rituximabs on the AFM tip bound to the CD20s on the cell surface during the contact between tip and cell, then the CD20-rituximab complexes were stretched by the AFM tip in the retracting process, causing a specific nonlinear shape of the force curve (the III portion in Fig. 5A ). This is caused by the nonlinear elasticity of the PEG crosslinker and with this feature we can readily distinguish between unspecific and receptor-specific binding (Carvalho & Santos, 2012) . From the inset of Figure 5A , we can clearly see the stretching process of CD20-rituximab complex. When the force exerted by the AFM tip was larger than the CD20-rituximab bond, the CD20-rituximab bond ruptured and there was an abrupt peak in the retract curve. In the experiments, the rituximab density attached to the AFM tip was controlled to be low to ensure that only one CD20-rituximab pair formed during each approach-retract cycle. Hence each force curve that had specific unbinding peak corresponded to a single CD20-rituximab binding event. The magnitude of the peak (denoted by the double-headed arrow in Fig. 5A ) corresponded to the binding force of CD20-rituximab. For comparison, functionalized tips were used to obtain force curves on normal cells (red blood cells) which do not express CD20. Figure 5 (B) was a typical force curve on red blood cells. We can see that there was no specific unbinding peak in the retract curve. This is because that CD20 is only expressed on B cells and red blood cells do not express CD20. Figure 5(C) shows the comparison of the adhesion forces of tumour cells and normal cells. We can see that the adhesion force of tumour cells were significantly larger than that of normal cells. This is because that the adhesion forces on tumour cells were specific CD20-rituximab forces, whereas the adhesion forces on normal cells were nonspecific forces which were less than specific molecular forces (Dupres et al., 2005) . A crucial issue in SMFS studies is to demonstrate the specificity of the measured unbinding forces (Hinterdorfer & Dufrene, 2006) . To confirm the specific CD20-rituximab interactions, force curves were obtained after adding free rituximabs to block the CD20s on the cell surface, and the results (Fig. 5D ) indicated that the specific binding frequency remarkably decreased after blocking, which demonstrated the specific CD20-rituximab interactions. Figure 6 shows the nanoscale distribution of CD20 on the surface of tumour cells. To map the nanoscale distribution of CD20 on the cell surface, 16×16 force curves at the 500×500 nm 2 local area on the cell surface were obtained. After computing the forces of these force curves, the adhesion force maps were constructed, as shown in Figure 6(A-D) . Because we controlled the density of rituximab linked onto the AFM tip to ensure that only one CD20-rituximab pair formed in each approach-retract cycle, each grey and bright pixels in the adhesion maps corresponded to a CD20 on the cell surface. The colour scale of the adhesion force map was 100 pN. From the adhesion force maps, we can see that some CD20s assembled together (denoted by the red dashed circles in Fig. 6A-C) , and some CD20s distributed sparsely on the cell surface (Fig. 6D) . In the previous researches, we found that the CD20 on the lymphoma tumour cell distributed sparsely and irregularly on the cell surface (Li et al., 2013b) . In this work, we found that CD20s on some tumour cells notably assembled together (Fig. 6A-C) . This may due to the heterogeneity of individual cells. Evidence has shown that genetically identical cells can display variable behaviours (Pelkmans, 2012) , which arises from dynamic adaptations to the microenvironment of individual cells (Snijder et al., 2012) . Now the challenge is to determine which components of observed cellular heterogeneity serve a biological function or contain meaningful information (Altschuler & Wu, 2010) . Researches have indicated that CD20s are not expressed in monomeric form, but organized into heterogeneous supramolecular complexes associating CD20 dimers or tetramers (Cartron et al., 2004) . Here from the adhesion force maps, we can clearly see that CD20s were heterogeneously distributed on the cell surface. We know that cell membrane is a heterogeneous membrane which has many compartments caused by the lipid rafts (Li et al., 2013b) and caveolae (Parton & Simons, 2007) . Hence the heterogeneity of cell membrane may be related to the heterogeneous distribution of CD20 on the tumour cells. Due to the 200 nm resolution limit, traditional biochemical methods can not reveal the nanoscale distribution of membrane proteins on the cell surface. With AFM functionalized tips, adhesion force maps that directly visualize the distribution of membrane proteins on the cell surface can be obtained (Dupres et al., 2005) , which is useful for understanding the membrane proteins. For comparison, adhesion force maps were also obtained on normal cells (red blood cells). Figures 6(E-H) were the typical adhesion force maps on red blood cells. We can see that there were almost none grey and bright pixels in the adhesion force maps. Red blood cells do not express CD20 antigen, and thus there were no specific molecular binding events in the SMFS measurements. The results of Figures 5 and 6 indicated that AFM is a useful tool to visually characterize the nanoscale distribution of membrane proteins on the cell surface.
By applying the established method described above on the bone marrow cells from three clinical B-cell NHL patients, we obtained the binding affinity and nanoscale distribution of CD20 on the tumour cells for the three patients, as shown in Figure 7 . To investigate the CD20 affinity and nanoscale distribution of different lymphoma patients, we selected three B-cell NHL patients for the study. All of the three patients were with bone marrow infiltration. ROR1 fluorescence labelling experiments were performed to confirm that there were ROR1s on the tumour cell surface of the three patients. The clinical information of the three patients were shown in Table 1 . For each patient, their bone marrow cells were dropped onto the glass slides and subsequent chemical fixation and ROR1-fluorescence labelling was performed. And then under the guidance of ROR1 fluorescence, about 10 tumour cells were selected and arrays of force curves were obtained on five different local areas on the surface of each cell using functionalized AFM tips. Figures 7(A-C) were the CD20 binding affinities of tumour cells from patient 1, patient 2 and patient 3, respectively. The CD20 binding affinities to rituximab were computed from the force curves which had specific molecular unbinding peaks. From the histogram, the Gaussian fitting indicated that the CD20 binding affinities of the three patient were 78 ± 33 pN, 88 ± 66 pN, 80 ± 39 pN, respectively. We can see that the binding affinities were not remarkable variable between the three patients. Figure 7 (D) shows the typical adhesion force maps of the three patients. To quantitatively characterize the nanoscale distribution of CD20s, we calculate the CD20 distribution frequency for each adhesion force map to characterize the CD20 density of the cells. For each adhesion force map, we can compute the number of grey and bright pixels (n), and the number of overall pixels of the adhesion force map was known (16×16 = 256). The CD20 distribution frequency of this adhesion force map was equal to the ratio (n/256). Figure 7 (E) shows the CD20 distribution frequencies of the three patients. Analyzing the relationship between CD20 density and clinical therapy outcomes, we can find some interesting phenomenon. The combined therapy (rituximab+chemotherapy) was effective for patient 1 and patient 3, but was ineffective for patient 2. The histogram of distribution frequencies indicated that the CD20 density of patient 2 was the smallest. This indicated that if there were more CD20 on the surface of tumour cells, the clinical efficacy was better. However, the efficacy of patient 3 was worse than the efficacy of patient 1, whereas the CD20 density of patient 3 was larger than the CD20 density of patient 1. This indicated that the therapy effects were not linearly proportional to the CD20 density of the tumour cells. The experimental results showed that the clinical efficacy of rituximab was to some extent related to the CD20 density and the relationship was not linear but may be complicated. We know that the main theory in pharmacology to characterize the efficacies of drugs is receptor theory (Kenakin, 2004) . Drugs produce therapeutic effects by binding to the receptors on the cell surface. Hence it is reasonable that when more drug molecules bind to the receptors on the cell surface, the effects become stronger. But the drug effects are not linearly proportional to the number of receptors occupied and the maximum effect can be produced by a drug when occupying just only a small proportion of the receptors (Stephenson, 1956) . The experimental results here indicated that the variance of CD20 binding affinities were not prominent among the three lymphoma patients in the study here, whereas the CD20 density of tumour cells was related to the efficacy of the clinical treatment. When rituximabs bind to the CD20s on the tumour cell, the Fc domains of rituximab can bind to the Fc Receptors (FcRs) on the effector cells which can then kill the tumour cells. The Fc domains of rituximab can also activate the classical complement pathway which eventually cause the lysis of the tumour cells (Glennie et al., 2007) . Compared to the binding affinity between CD20 and rituximab, the CD20 density on the cell surface may play a more important role in the rituximab's therapy effects. If there are more CD20s on the tumour cell surface, then possibly more rituximabs can bind to the cell surface and more effector cells can be recruited which causes that the therapy effects become stronger. But there may exist a threshold of the number of CD20 on the surface of tumour cells. If the number of CD20s exceed this threshold, the efficacies of rituximab do not increase, as the observed phenomenon of patient 1 and patient 3. Researchers (van Meerten et al., 2006) have investigated the relationship between CD20 expression level and rituximabmediated cell kill and the results indicated that rituximabinduced CDC clearly depends on the CD20 expression level. In the rituximab's killing mechanisms, rituximab display a remarkable ability to activate complement and elicit CDC (Beers et al., 2010) . These evidences indicated that CD20 expression is closely related to the therapeutic effects of rituximab. However, exactly elucidating the mechanisms that determine the clinical efficacies of rituximab is a challenge. First, though the rituximab's three mechanisms have been demonstrated in vitro, the situations in vivo are not unknown. Limited by the technique, we now can not investigate the drug actions in the human body, meaning that we can only obtain conclusions by indirect methods (e.g. in vitro test and animal model) which can not reflect the real behaviours in the human (Junttila & Sauvage, 2013) . Second, the rituximab is typically combined with chemotherapy in the practice, and thus the contribution of rituximab to the efficacy is difficult to evaluate (Rezvani & Manoney, 2011) . Third, the problem of Rituximab's variable efficacies among different patients is complicated, and various aspects need to be taken into consideration, such as tumour profiling, analysis of the microenvironment, assessment of host immune effector function and genetic polymorphisms of FcR (Alduaij & Illidge, 2011) . Here we investigated the relationship between CD20 density of tumour cells and the clinical therapy effects and the results indicated that the therapy effects are related to the CD20 density in a certain range. However, we only investigated three clinical lymphoma cases, and more cases are needed to be investigated in the future to obtain a robust result.
In the future, we want to collect more lymphoma cases to investigate the biophysical properties of tumour cells. Besides the binding affinity and distribution of CD20 on the tumour cells, we would like to measure the binding affinity and distribution of FcRs on the effector cells (e.g. NK cell, macrophage) from the patients. We know the efficacies of rituximab are not only related to the tumour but also related to the host immune systems. In the ADCC action of rituximab, rituximab binds to the CD20 on the tumour cells, and then the Fc domain of rituximab binds to the FcR on the effectors. We can see that two types of molecular interactions occur in ADCC, including CD20-rituximab and FcR-rituximab. Many experiments have demonstrated that FcR plays a central role in the killing mechanism of rituximab (Glennie et al., 2007) , and several new anti-CD20 antibodies (e.g., Ofatumumab, Ocrelizumab, Veltuzumab, AME-133V, PRO131921, GA101) with enhanced FcR-mediated effector functions have been developed for clinical trials (Alduaij & Illidge, 2011) . Clinical trials of these new antibodies will help us to know which mechanism of rituximab is indispensable in the therapy (Weiner, 2010) . Consequently, simultaneously measuring the molecular interactions of CD20-rituximab and FcR-rituximab will significantly improve our understanding of rituximab action and may bring meaningful information.
In summary, we investigated the nanoscale distribution of CD20 directly on tumour cells under the guidance of ROR1 fluorescence labelling by using AFM single-molecule technique, and analyzed the relationship between CD20 distribution and the clinical therapeutic effects of rituximab. The analysis of CD20 distribution of three clinical B-cell NHL patients indicated that CD20 distribution has a direct impact on the clinical efficacies of rituximab. The experimental results can improve our understanding of rituximab's effects from the nanoscale distribution of CD20 on the surface of tumour cells and will facilitate further researches of rituximab's variable efficacies among different patients.
